Loading
Genecast's personalised blood test for leftover cancer, used to follow patients with EGFR-mutated lung cancer after surgery in the EVIDENCE trial.
MinerVa Prime is the personalised residual disease assay of Genecast Biotechnology of Wuxi. Its largest published use is the MRD analysis of the phase 3 EVIDENCE trial of adjuvant icotinib versus chemotherapy in resected stage II to IIIA EGFR-mutated non-small cell lung cancer (Zhou et al., Nature Communications 2026): 1,352 plasma samples from 175 patients. At the landmark it found residual disease in 35.8 per cent of stage III and 14.7 per cent of stage II patients, with a longitudinal positivity of 47.4 per cent; positivity was associated with shorter disease-free survival at the landmark (hazard ratio 4.44) and over follow-up (7.82), longitudinal negative predictive value was 91.3 per cent, and median lead time over clinical recurrence was 169 days.
Tumour whole-exome sequencing selects up to 52 patient-specific variants, read in plasma together with a fixed panel of more than 1,000 mutation hotspots.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MinerVa Prime" OR ABSTRACT:"MinerVa Prime" OR TITLE:"Genecast MinerVa Prime" OR ABSTRACT:"Genecast MinerVa Prime") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MinerVa Prime, not a curated reading list.
Shares brPROPHET, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/